NCT05487196

Brief Summary

The purpose of this randomized controlled trial is to compare the effectiveness of epidural clonidine, dexmedetomidine, or fentanyl adjuncts for labor analgesia.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
88

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Sep 2022

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 2, 2022

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 4, 2022

Completed
2 months until next milestone

Study Start

First participant enrolled

September 28, 2022

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2023

Completed
1.7 years until next milestone

Results Posted

Study results publicly available

April 27, 2025

Completed
Last Updated

April 27, 2025

Status Verified

April 1, 2025

Enrollment Period

10 months

First QC Date

August 2, 2022

Results QC Date

July 28, 2024

Last Update Submit

April 9, 2025

Conditions

Keywords

PregnancyVaginal DeliveryEpidural Labor Analgesia

Outcome Measures

Primary Outcomes (1)

  • Pain Burden, AUC (30 Minutes)

    Pain score AREA UNDER THE CURVE (AUC), which is a calculated area under curve using the trapezoidal rule, where pain scores measured from 0 (no pain) to 10 (worst imaginable pain) are on the y axis, and time is on the x axis (pain scores were measured at 5 minutes, 10 minutes,15 minutes, 30 minutes after epidural initiation for the primary outcome assessment). The scale for AUC is not 0-10 but rather is completely dependent upon the area generated under the curve created by pain scores for the first 30 minutes of epidural analgesia (primary outcome time frame): in this case, the scale is 0-250 pain units\*minute, given maximum pain score possibility of 10 and time period of 30 minutes. The units of AUC are the units of Y axis times units of X axis, in this case, pain score units \* minutes. Pain AUC was compared between Fentanyl, Clonidine and Dexmedetomidine groups.

    First 30 minutes of analgesia

Secondary Outcomes (12)

  • Pain Burden, AUC (120 Minutes)

    First 120 minutes of analgesia

  • Pain Scores

    15 minutes after initiation of epidural analgesia

  • Pain Scores

    30 minutes after initiation of epidural analgesia

  • Pain Scores

    Immediately after delivery

  • Cesarean Delivery

    At the time of delivery

  • +7 more secondary outcomes

Study Arms (3)

Clonidine

EXPERIMENTAL

Bolus dose at epidural initiation, through the epidural catheter: 10 ml Ropivacaine 0.1 % combined with a single dose of Clonidine 60 mcg

Drug: ClonidineDrug: Ropivacaine

Dexmedetomidine

EXPERIMENTAL

Bolus dose at epidural initiation, through the epidural catheter: 10 ml Ropivacaine 0.1 % combined with a single dose of Dexmedetomidine 30 mcg

Drug: DexmedetomidineDrug: Ropivacaine

Ropivacaine + Fentanyl

ACTIVE COMPARATOR

Bolus dose at epidural initiation, through the epidural catheter: 10 ml Ropivacaine 0.1 % combined with a single dose of Fentanyl 100mcg

Drug: FentanylDrug: Ropivacaine

Interventions

Clonidine belongs to the drug classification of antihypertensives

Clonidine

Dexmedetomidine belongs to the drug classification of sedatives

Dexmedetomidine

Fentanyl belongs to the drug classification of analgesic opioid agonists and is used as the standard of care

Ropivacaine + Fentanyl

Ropivacaine belongs to the drug classification of local or regional anesthesia for surgery and is used as standard of care

ClonidineDexmedetomidineRopivacaine + Fentanyl

Eligibility Criteria

Age18 Years - 65 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Pregnant women greater than 18 years of age
  • American Society of Anesthesiologists (ASA) Physical Status 2 or 3
  • Term pregnancy (greater than 37 gestational weeks)
  • Planning epidural labor analgesia
  • Singleton pregnancy
  • Vertex presentation
  • Planned vaginal delivery

You may not qualify if:

  • Pre-eclampsia with or without severe features
  • New initiation of antihypertensive agent within 24 hours prior to enrollment
  • Uncontrolled systemic comorbidities \[i.e., diabetes, hepatic, renal or cardiac\]
  • Known or suspected fetal abnormalities
  • Allergy to study agents
  • Contra-indication to neuraxial anesthesia
  • Inability to communicate or participate in study procedures

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UPMC Magee-Womens Hospital

Pittsburgh, Pennsylvania, 15213, United States

Location

MeSH Terms

Interventions

ClonidineDexmedetomidineFentanylRopivacaine

Intervention Hierarchy (Ancestors)

ImidazolinesImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsPiperidinesAnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Limitations and Caveats

The primary limitation of this study is related to the clonidine and dexmedetomidine doses used for analgesia initiation. The doses were chosen based on what was available in existing literature and clinical experience. Another limitation is that many patients who were eligible and approached declined participation, citing lack of interest in research or primarily a desire to receive only current institutional standards for epidural labor analgesia.

Results Point of Contact

Title
Dr. Grace Lim, MD, MSc
Organization
UPMC Magee Women's Hospital

Study Officials

  • Grace Lim, MD, MS

    University of Pittsburgh

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: This study is designed as a randomized, quadruple blinded, parallel arm, controlled, non-inferiority trial in 3 groups allocated in a 1:1:1 ratio
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

August 2, 2022

First Posted

August 4, 2022

Study Start

September 28, 2022

Primary Completion

July 31, 2023

Study Completion

July 31, 2023

Last Updated

April 27, 2025

Results First Posted

April 27, 2025

Record last verified: 2025-04

Data Sharing

IPD Sharing
Will not share

Locations